Isolate. Investigate. Manipulate. Simulate.
Improving health and changing lifes one molecule at a time: nanotechnology and analytics to develop innovative biotechnology platforms.
DNA-sequencing approaches the 1000-Dollar-Genome milestone allowing for decoding a complete human genome with unmatched speed and at low cost. Increased sequencing efficiency yields massive amounts of genomic data. Analysis of this data eventually enables understanding the role of DNA segments and their correlation with the risk of developing a certain disease. New drug targets are discovered continuously and can be matched with a personalized genetic risk assessment. Access to this information triggers fundamental questions for doctors and patients alike: What are the chances of an outbreak? Are drugs available? What is the best combination of prevention and treatment? In order to provide answers, technologies for discovering novel drugs, for improving existing drugs and for their intelligent use in an increasingly complex environment, will have to be revolutionized. The path from personalized sequencing via genetic data analysis towards personal prevention and treatment will reshape medicine as we know it. The Bio-Nanosensors group of the IBM Australia Research Laboratory works at the forefront of this process: we develop bio-nanosensor chips for next-generation drug screening & discovery as well as diagnostic applications of life sciences research – we are helping to re-invent personalized medicine, the next big thing emerging from marrying nanotechnology and biotechnology.
Metal solid-state nanopore filled with water and glycerol
March 2015 - Natalie Gunn from #IBMResearch Australia is conducting experiments using small angle x-ray scattering (SAXS) to determine the size and shape of fluorescent molecules in solution. #InTheLab